These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30745501)

  • 1. The effect of disease activity on thyroid nodules in patients with acromegaly.
    Kan S; Kizilgul M; Celik B; Beysel S; Caliskan M; Apaydin M; Ucan B; Cakal E
    Endocr J; 2019 Apr; 66(4):301-307. PubMed ID: 30745501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The thyroid gland in acromegaly: an ultrasonographic study.
    Cheung NW; Boyages SC
    Clin Endocrinol (Oxf); 1997 May; 46(5):545-9. PubMed ID: 9231049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
    Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
    Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.
    Chin SO; Chung CH; Chung YS; Kim BJ; Kim HY; Kim IJ; Kim JG; Kim MS; Kim SY; Lee EJ; Lee KY; Kim SW
    BMJ Open; 2015 Jun; 5(6):e006898. PubMed ID: 26063564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
    Lorcy Y; Dejager S; Chanson P;
    Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up.
    Cannavò S; Squadrito S; Finocchiaro MD; Curtò L; Almoto B; Vieni A; Trimarchi F
    Horm Metab Res; 2000 May; 32(5):190-5. PubMed ID: 10871160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
    J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.